Showing results (431-440 of 10,436) with videos related to

Sort By:
Pageof 1,044
AIDS (London, England)|May 29, 2004
23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohortChristine Watera, Jessica Nakiyingi, George Miiro, et al.
AIDS (London, England)|April 20, 2004
Healthcare use by varied highly active antiretroviral therapy (HAART) strata: HAART use, discontinuation, and naivetyHerminia Palacio, Xiuhong Li, Tracey E Wilson, et al.
AIDS (London, England)|April 20, 2004
The metabolic effects of lopinavir/ritonavir in HIV-negative menGrace A Lee, Tara Seneviratne, Mustafa A Noor, et al.
AIDS (London, England)|April 20, 2004
Differences in HIV-2 plasma viral load and immune activation in HIV-1 and HIV-2 dually infected persons and those infected with HIV-2 only in Abidjan, Côte D'IvoireStéphania Koblavi-Dème, Luc Kestens, Debra Hanson, et al.
AIDS (London, England)|April 20, 2004
Defective interleukin-2-dependent STAT5 signalling in CD8 T lymphocytes from HIV-positive patients: restoration by antiretroviral therapyMarko Kryworuchko, Virginie Pasquier, Hélène Keller, et al.
AIDS (London, England)|April 20, 2004
Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patientsSusan D Driscoll, Gary E Meininger, Mark T Lareau, et al.
AIDS (London, England)|April 20, 2004
HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1Danuta Pieniazek, Mark Rayfield, Dale J Hu, et al.
AIDS (London, England)|April 20, 2004
Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavirChristoph Stephan, Nils von Hentig, Irene Kourbeti, et al.
AIDS (London, England)|April 20, 2004
Five-year follow-up of a cohort of profoundly immunosuppressed patients discontinuing therapy for cytomegalovirus retinitisPeter A Sklar, Amma F Agyemang, Rachelle Monastra, et al.
AIDS (London, England)|April 20, 2004
Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?Alan Winston, Anton Pozniak, Nicola Smith, et al.
Pageof 1,044